Novartis disputes U.S. senators’ report over Cohen contract

Home Investment Novartis disputes U.S. senators’ report over Cohen contract
Novartis disputes U.S. senators’ report over Cohen contract

Novartis disputes U.S. senators' report over Cohen contract

ZURICH (Reuters) – Novartis (S:) on Friday disputed a report from Democratic U.S. senators that concluded the Swiss drugmaker made misleading statements about its $1.2 million contract with a former attorney for President Donald Trump.

"We disagree with the report's conclusion that we issued a misleading public statement regarding the extent of our engagement with (Michael) Cohen," Novartis said of the report compiled by staff of Sen. Ron Wyden, from Oregon, that concluded the company's relationship with Cohen was longer and more detailed than it had previously disclosed.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Leave a Reply

Your email address will not be published.